Results 91 to 100 of about 57,759 (194)

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death

Cell Death Discovery
Glioblastoma is an incurable brain tumor with a median survival below two years. Trials investigating targeted therapy with inhibitors of the kinase mTOR have produced ambiguous results.
Benedikt Sauer, Nadja I. Lorenz, Iris Divé, Kevin Klann, Anna-Luisa Luger, Hans Urban, Jan-Hendrik Schröder, Joachim P. Steinbach, Christian Münch, Michael W. Ronellenfitsch   +9 more
doaj   +1 more source

Programmable Dimensional Lithography with Digital Micromirror Devices for Multifunctional Microarchitectures

Advanced Materials Technologies, Volume 11, Issue 5, 6 March 2026.
This review explores recent advances in digital micromirror device (DMD)‐based lithography, focusing on its programmable light modulation, multi‐material compatibility, and dimensional patterning strategies. It highlights innovations from optical system design to materials integration and multifunctional applications, positioning DMD lithography as a ...
Yubin Lee, Byungcheon Yoo, Chaeyeong Ryu, Jongwon Oh, Dahye Baek, Jiseok Lee   +5 more
wiley   +1 more source

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

Journal of Translational Medicine
Background In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM ...
Paola Matarrese, Michele Signore, Barbara Ascione, Giulia Fanelli, Marco G. Paggi, Claudia Abbruzzese   +5 more
doaj   +1 more source

Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F‐Actin Formation and Facilitate Double‐strand DNA Breaks Repair in TMZ‐Resistant Glioblastoma

Advanced Science, Volume 13, Issue 13, 3 March 2026.
This study revealed that low expression of YTHDC1 in TMZ‐resistant GBM cells leads to increased FSCN1 expression, which is suppressed by m6A modification. FSCN1 activates the CDC42/N‐WASP/Arp2/3 axis in the cell nucleus by recruiting the guanine nucleotide exchange factor (GEF) family member FGD1, thereby promoting F‐actin polymerization in the nucleus.
Minglong Yang, Wanxiang Niu, Yuanfei Wang, Peng Chen, Maolin Mu, Xiaoming Zhang, Ben Xu, Shanshan Hu, Chaoshi Niu, Pengfei Wu   +9 more
wiley   +1 more source

Application progress of temozolomide in clinical tumor chemotherapy

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
Temozolomide is an imidazotetrazine derivative of the alkylating agent, which is used to treat central nervous system tumors, especially malignant brain gliomas. It is a milestone in brain giloma chemotherapy. Recently, some researchers used temozolomide
Cheng ZHONG, Bin WANG, Sheng-qing LV
doaj  

A Language Performance Model for Predicting Glioma Recurrence and Molecular Biomarkers: A Retrospective Cohort Study

Brain and Behavior, Volume 16, Issue 3, March 2026.
This study proposes a language‐based prognostic model for glioma recurrence by analyzing preoperative language performance using the Aphasia Battery of Chinese in 191 patients with WHO grade 2–4 gliomas. Principal component analysis and Cox regression identified key language predictors, which were used to construct and internally validate the language ...
Hua Song, Linghao Bu, Chen Luo, Luhao Yang, Shuai Wu, Jie Zhang, Ye Yao   +6 more
wiley   +1 more source

SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment

CNS Neuroscience &Therapeutics, Volume 32, Issue 3, March 2026.
SMPD1 expression varies across different glioma subtypes and clinical features and is associated with poor prognosis. High SMPD1 levels are linked to an immunosuppressive tumor microenvironment, characterized by suppressed M1 macrophage polarization and enhanced M2‐like signatures.
Yanan Xu, Xing Liu, Boya Xu, Qiuling Li, Luofei Zhang, Cao Li, Zhigang Zhao   +6 more
wiley   +1 more source

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Terhi K. Friman, Birgitta Salmela, Ilkka Helanterä, Fredrik Åberg, Timo Jahnukainen, Maija Halme, Samuli Vaittinen, Jyri Lommi, Markku O. Pentikäinen, Panu E. Kovanen, Sirpa Leppä, Riikka Räty   +11 more
wiley   +1 more source

Anatomical Localization–Based Analysis of Relapsed Secondary Central Nervous System Aggressive B‐Cell Lymphoma (R‐SCNSL)

Hematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT 162 patients with relapsed secondary central nervous system lymphoma (R‐SCNSL) (median age, 65 years; male, 59.9%) including central nervous system (CNS)‐only (n = 120) and concomitant CNS/systemic relapse (n = 42) were retrospectively analyzed.
Izel Okcu, Yucai Wang, Zhuo Li, Launia J. White, Patrick B. Johnston, Allison C. Rosenthal, Jonas Paludo, Rebecca L. King, Thomas E. Witzig, Thomas M. Habermann, Grzegorz S. Nowakowski, Han W. Tun   +11 more
wiley   +1 more source

Quercetin and Its Nano‐Based Formulations Against Skin Cancer: A Narrative Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background Skin cancer is one of the most prevalent malignancies worldwide, characterized by the abnormal growth of skin cells and significant clinical challenges. Conventional treatments—including surgery, chemotherapy, and radiotherapy—often suffer from limitations such as adverse side effects, tumor resistance, and inadequate efficacy.
Mahtab Khanyabzadeh, Alireza Emamifar, Nikoo Emtiazi, Amir Nazari, Masoumeh Shekarriz, Amin Karami, Fateme Hashem Beik Mahallati, Rahineh Nomani Lafmejani, Atieh Dariush, Seyed Mohammad Mahdi Rohani, Elaheh Mohseni Vadeghani, Negin Khoshnood, Hamid Reza Ojaghi, Fatemeh Rezaei‐Tazangi, Reza Arefnezhad   +14 more
wiley   +1 more source